Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
20 December 2024 - 12:00AM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse
Biosciences”), a novel bioelectric medicine company commercializing
the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™)
technology, today announced that, on December 18, 2024, the
Company’s Co-Chairman and majority shareholder, Robert W. Duggan,
exercised all of the warrants he acquired in the Company’s 2024
rights offering, corresponding to $58.4 million totaling to
5,306,156 shares of Company common stock. Mr. Duggan also confirmed
that, from December 11, 2024 through this past Friday, December 13,
2024, he has purchased an additional 156,714 shares of Pulse
Biosciences. These transactions bring Mr. Duggan’s current
ownership in the Company to approximately 70%.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary CellFX®
nsPFA™ technology delivers nanosecond pulses of electrical energy
to non-thermally clear cells while sparing adjacent noncellular
tissue. The Company is actively pursuing the development of its
CellFX nsPFA technology for use in the treatment of atrial
fibrillation and in a select few other markets where it could have
a profound positive impact on healthcare for both patients and
providers. Pulse Biosciences is now headquartered in Miami, Florida
and maintains its office in Hayward, California.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA,
CellFX nsPFA and the stylized logos are among the trademarks and/or
registered trademarks of Pulse Biosciences, Inc. in the United
States and other countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241219059064/en/
Investors: Pulse Biosciences, Inc. Darrin Uecker, CTO or
Kevin Danahy, CCO IR@pulsebiosciences.com or Gilmartin Group Philip
Trip Taylor 415.937.5406 philip@gilmartinir.com
Rights Offering Information, Subscription and Warrant
Agent: Broadridge Corporate Issuer Solutions, LLC Attn: BCIS
Re-Organization Dept. P.O. Box 1317 Brentwood, NY 11717-0718
888.789.8409 shareholder@broadridge.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Dec 2024 to Jan 2025
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Jan 2024 to Jan 2025
